Nkarta (NASDAQ:NKTX) Posts Earnings Results, Misses Estimates By $0.05 EPS

Nkarta (NASDAQ:NKTX) posted its quarterly earnings results on Thursday. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05), FiscalAI reports.

Nkarta Price Performance

Shares of NASDAQ NKTX traded up $0.16 on Friday, hitting $1.73. The company’s stock had a trading volume of 2,000,682 shares, compared to its average volume of 1,137,618. The stock has a 50 day moving average of $2.34 and a 200-day moving average of $2.51. The company has a market capitalization of $123.90 million, a price-to-earnings ratio of -1.00 and a beta of 1.24. Nkarta has a 12-month low of $1.48 and a 12-month high of $3.72.

Analysts Set New Price Targets

NKTX has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of Nkarta from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Stifel Nicolaus lowered their target price on shares of Nkarta from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. HC Wainwright started coverage on shares of Nkarta in a report on Monday, November 2nd. They issued a “buy” rating for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nkarta in a research report on Monday, September 21st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Nkarta presently has a consensus rating of “Moderate Buy” and an average price target of $11.20.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s platform is designed to produce allogeneic, or donor-derived, NK cells that can be engineered with chimeric antigen receptors (CARs) to recognize and attack targeted cells.

Nkarta’s research and development programs have included NKX019, a CD19-targeted CAR NK-cell therapy investigated for B-cell malignancies and autoimmune disorders, and NKX101, an NKG2D-targeted CAR NK-cell therapy developed for certain solid tumors.